Page 234 - WSAVA2018
P. 234

 25-28 September, 2018 | Singapore
alone. Criteria suggestive for lymphoma over IBD include a more monomorphic lymphocyte population, specific patterns of epitheliotropism and/or lamina propria invasion, extension deep to the mucosa, and intravascular infiltration. In addition to routine H&E, immunophenotyping with immunohistochemistry (IHC) and assessment of clonality via PCR (PARR)
can assist in making a final diagnosis of lymphoma.
In one study (2), approximately 50% of cases that were initially diagnosed as IBD on H&E alone
were re-classified as T cell lymphoma when IHC
and PARR were assessed. Although less common, misdiagnosis of IBD as lymphoma can also occur. This study suggested a diagnostic algorithm for these cases - if initial histopathology diagnoses IBD but there is poor response to treatment then IHC
+/- PARR should be pursued for definitive diagnosis. If initial biopsy is suspicious for lymphoma then IHC should be performed +/- PARR, if IHC is suspicious but not diagnostic for lymphoma. If initial biopsy diagnoses lymphoma, IHC is still recommended for immunophenotyping as prognosis may differ for B versus T cell disease, and because of the small risk of false positive lymphoma diagnosis. PARR should not be relied upon alone for diagnosis as sensitivity in cats can vary (as low as 60-70%, especially with
B cell lymphoma) therefore a negative result cannot conclusively rule out lymphoma.
Nasal lymphoma: Lymphoma is the most common intranasal tumour in cats. Clinical signs do not specifically distinguish it from other intranasal diseases. In most
cats, it is localised to the nasal cavity at diagnosis, though systemic involvement can occur. Advanced imaging (CT or MRI) and biopsies for histopathology
are recommended for diagnosis - while cytology
may be diagnostic, false negatives are common due
to concurrent inflammation. Radiation therapy is the treatment of choice for localised disease. Complete staging including regional lymph nodes, thoracic
and abdominal imaging and ideally bone marrow assessment, is recommended if radiation therapy is to be pursued.
Conundrums:
· Definitive diagnosis: IHC is the most reliable way
to distinguish nasal lymphoma from carcinoma (the second most common feline intranasal tumour) and should be considered for definitive diagnosis in all feline nasal tumours (3). Although the recommended treatment for both is radiation therapy and the error rate of routine H&E is not especially high, lymphoma has a higher risk of systemic involvement and therefore more extensive staging is indicated prior to treatment, and the prognoses differ (generally longer survival time with lymphoma than carcinoma). IHC on feline nasal tumours, especially those diagnosed as carcinoma on H&E, would therefore seem prudent.
· Treatment options: Although radiation is standard of care, it is not widely available. In that case, chemotherapy can be effective. The majority of cats will respond to COP/CHOP chemotherapy and extended survivals can be seen, especially in those achieving a complete response (approximately 1-2 years) (4).
· Combining radiation with chemotherapy: Given
the risk of systemic disease and the effectiveness of chemotherapy, it is tempting to treat with both radiation therapy and chemotherapy. In one study using radiation therapy and chemotherapy for cats with localised nasal lymphoma, the median survival time was approximately 2.5 years, longer than that published for either treatment alone (5). The one study comparing cats treated with radiation therapy, chemotherapy, or both, for nasal lymphoma did not show a statistically significant difference between the treatments, though when cats receiving any radiation therapy were compared to cats receiving chemotherapy alone, radiation therapy was found to improve overall survival time. Again, improved survival was seen in cats with a complete response to treatment (6).
Peripheral nodal lymphoma: Lymphoma limited to the peripheral nodes represents < 10% of all feline lymphoma cases. Nodal lymphoma in cats includes both small
and large cell variants, and there is a specific subtype referred to as “Hodgkin’s-like” which typically involves one or more of the lymph nodes of the head and neck.
· How much does the distinction of IBD versus
small cell lymphoma matter? Prognosis for IBD is better than small cell lymphoma, and a definitive diagnosis should always be pursued. However, in cases where IBD or small cell lymphoma is strongly suspected based on initial diagnostic tests, and histopathology is either not definitive or is declined by owners, initiating treatment directed at IBD and escalating if response is inadequate (e.g. diet and B12 supplementation if indicated → prednisolone
→ chlorambucil) may be, in my opinion, very reasonable. Distinguishing between aggressive
GI lymphoma and small cell lymphoma is of vital importance as the treatment options and prognosis are dramatically different.
· Does a prior diagnosis of IBD increase the risk of developing lymphoma in the future? In cats with a previous diagnosis of IBD who are later diagnosed with small cell lymphoma, it is unclear whether 1)
IBD has ‘transformed’ into lymphoma or the chronic inflammation has potentiated the development of lymphoma or 2) the initial diagnosis was incorrect and the cat had lymphoma all along. In people, inflammatory bowel disease is strongly associated with an increased risk of colorectal cancer. These cancers are typically carcinomas, although there may be an increased risk of lymphoma as well. Chronic immunosuppression may also play a role in cancer risk in these patients.
  232
43RD WORLD SMALL ANIMAL VETERINARY ASSOCIATION CONGRESS AND 9TH FASAVA CONGRESS





































































   232   233   234   235   236